Lantus/Lixisenatide Combo Gets FDA Panel Nod, But Not Sanofi's Device
This article was originally published in The Pink Sheet Daily
Pen for iGlarLixi should be redesigned to reduce risk of confusion and medication errors, advisory committee members say.
You may also be interested in...
US FDA approves Xultophy and Soliqua, both fixed-ratio combinations of a basal insulin and a GLP-1 agonist, on the same day even though Sanofi redeemed a priority review voucher that earned Soliqua an earlier user fee goal date.
FDA request for more information on pen injector forces three-month review extension, offsetting advantage from priority review voucher redemption.
The latest drug development news and highlights from our FDA Performance Tracker.